首页> 外文期刊>Biological & pharmaceutical bulletin >Histopathological Study of Kidney Abnormalities in an Experimental SIADH Rat Model and Its Application on the Evaluation of the Pharmacologic Profile of VP-343, a Selective Vasopressin V_2 Receptor Antagonist
【24h】

Histopathological Study of Kidney Abnormalities in an Experimental SIADH Rat Model and Its Application on the Evaluation of the Pharmacologic Profile of VP-343, a Selective Vasopressin V_2 Receptor Antagonist

机译:实验性SIADH大鼠模型中肾脏异常的组织病理学研究及其在评估选择性加压素V_2受体拮抗剂VP-343的药理作用中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this work was to investigate histopathologically the relationship between the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and kidney abnormalities and the therapeutic efficacy of VP-343 ((N-[4-[[(2S,3aR)-2-hydroxy-2,3,3a,4-tetrahydropyrrolo[1,2-a]qunoxalin-5(1H)-yl]phenyl]-4'-methyl[1,1'-biphenyl]-2-carboxamide], a selective vasopressin V_2 receptor antagonist, in an experimental SIADH rat model. In the model, which was prepared by continuously administering 1-desamino-8-D-arginine vasopressin (DDAVP), histopathologic abnormalities, such as dilatation of tubules, basophilic changes in tubules, inflammatory cell infiltration, and mineralization were found in the kidney, accompanied by significant increases in the relative weight of the kidney, lung, liver, adrenal gland, and heart. VP-343 was shown to be effective in protecting the kidney from the histopathologic abnormalities and to normalize the relative weight of the kidney and several common pathophysiologic features, such as hyponatremia, hyposmolarity of plasma, hyperosmolarity of urea, and oligurea, as described previously. These results demonstrate the occurrence of histopathologic abnormalities in the kidney and the efficacy of VP-343 in improving abnormalities in the DDAVP-induced SIADH rat model.
机译:这项工作的目的是组织病理学研究抗利尿激素分泌异常综合征(SIADH)和肾脏异常与VP-343((N- [4-[[(2S,3aR)-2 -羟基-2,3,3a,4-四氢吡咯并[1,2-a]喹诺沙林-5(1H)-基]苯基] -4'-甲基[1,1'-联苯] -2-羧酰胺],a SIADH大鼠模型中的选择性血管加压素V_2受体拮抗剂,该模型是通过连续施用1-desamino-8-D-精氨酸加压素(DDAVP)制备的,其病理组织学异常如肾小管扩张,肾小管嗜碱性改变肾脏中发现炎症细胞浸润和矿化,同时肾脏,肺,肝脏,肾上腺和心脏的相对重量显着增加,VP-343被证明可有效保护肾脏免受组织病理学损害异常并正常化肾脏的相对重量和几种常见的病态生理学特征,如低钠血症,血浆低渗,尿素高渗和尿少,如前所述。这些结果证明了肾脏中组织病理学异常的发生以及VP-343在改善DDAVP诱导的SIADH大鼠模型中的异常中的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号